|
|
Dendreon Corporation
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Dendreon Annual Meeting notesIf the label will cover 100,000 patients (and I assume they were referring to US only) @ $50,000/patient the addressable market would be $5B. Wow. The $50K number could be low based upon other biologics and the total cost of treating patients with Lupron or Taxotere. |
||||||||||||
|
|
return to message board, top of board |
